A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02213263.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationPfizer Inc

• Primary IDB3281006
• Secondary IDsNCI-2015-00476, 2014-000132-41, REFLECTIONS
• ClinicalTrials.gov IDNCT02213263